Skip to main content
. 2019 Apr 24;8(6):2858–2866. doi: 10.1002/cam4.2183

Table 2.

Clinicopathological features of EGFR concomitant or single mutation patients treated with first‐line EGFR‐TKI

  Concomitant n(%) Single n(%) P
Sex
Female 9 (81.8) 61 (61.0) 0.208
Male 2 (18.2) 39 (39.0)  
Age
˂65 7 (63.6) 59 (59.0) >0.9999
≥65 4 (36.4) 41 (41.0)  
Smoking status
Never/light 10 (90.9) 77 (77.0) 0.451
Smoking 1 (9.1) 23 (23.0)  
Pathology
Adenocarcinoma 11 (100.0) 91 (91.0) 0.595
Others 0 9 (9.0)  
Treatment effect
PR 7 (63.6) 66 0.613
SD 2 (18.2) 26  
PD 2 (18.2) 8